title: Design of bioartificial pancreas with functional micro/nano-based encapsulation of islets.
abstract: Type I diabetes mellitus (TIDM), a devastating health issue in all over the world, has been treated by successful transplantation of insulin secreting pancreatic islets. However, serious limitations such as the requirement of immunosuppressive drugs for recipient patients, side effects as a result of long-term use of drugs, and reduced functionality of islets at the transplantation site remain. Bioartificial pancreas that includes islets encapsulated within semi-permeable membrane has been considered as a promising approach to address these requirements. Many studies have focused on micro or nanobased islet immunoisolation systems and tested the efficacy of encapsulated islets using in vitro and in vivo platforms. In this review, we address current progress and obstacles for the development of a bioartificial pancreas using micro/nanobased systems for encapsulation of islets.
authors.forename: Burcu
authors.initials: B
authors.lastname: Kepsutlu
authors.forename: Caner
authors.initials: C
authors.lastname: Nazli
authors.forename: Tugba
authors.initials: T
authors.lastname: Bal
authors.affiliation: Koc University, Materials Science and Engineering, Istanbul, 34450, Turkey. skizilel@ku.edu.tr.
authors.forename: Seda
authors.initials: S
authors.lastname: Kizilel
mesh_terms: D000818:Animals; D021522:Bioartificial Organs; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D036103:Nanotechnology; D019397:Pancreas, Artificial
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin